Scabigard Suspension Class II Recall - Product Defect Affecting Efficacy
The UK Veterinary Medicines Directorate (VMD) has issued a Class II recall alert for Scabigard Suspension for Cutaneous Administration (Vm 42058/5173 and Vm 60021/3020) manufactured by Zoetis. The affected batches may fail to demonstrate expected signs of 'take' following administration. Nine batch numbers are affected, manufactured between June 2024 and January 2025, with expiry dates through December 2026. Wholesalers and veterinarians are required to immediately review inventory and quarantine affected products.
How MAHs Report Veterinary Medicine Defects
The UK Veterinary Medicines Directorate (VMD) has published guidance for Marketing Authorisation Holders (MAHs) on reporting product defects in veterinary medicines. MAHs must submit a completed Product defect report form to rapidalert@vmd.gov.uk and contact VMD to discuss recalls where a product or batch is likely to be recalled. The guidance also includes a table of recalled products from the last 12 months including recent recalls of Scabigard (April 2026), Hibiwash (March 2026), and Folltropin (November 2025).
Illegal Animal Medicines Seizures, Improvement Notices and Prosecutions
The Veterinary Medicines Directorate (VMD) publishes a rolling 12-month listing of enforcement actions under the Veterinary Medicines Regulations 2013 (VMR), including seizure notices, improvement notices, and prosecutions involving illegal animal medicines. The listing covers activities from August 2024 through April 2026, with updates added as enforcement actions occur. The VMD exercises powers of entry and inspector powers under the VMR to address non-compliance with animal medicine regulations.
VMD Published Standards 2025 to 2026: Monitoring Performance
The UK Veterinary Medicines Directorate (VMD) published its official statistics report monitoring performance against published standards for the period 2025 to 2026 up to 31 March 2026. The report includes monthly performance summaries from September 2025 through March 2026. This is an informational publication providing performance data rather than establishing new regulatory requirements.
Top Ten Imported Veterinary Medicines Quarterly Report Q1 2026
The UK Veterinary Medicines Directorate published its quarterly statistical report on certificates issued under the Special Import System for Q1 2026. Artuvetrin Therapy led with 3,256 certificates (27% of total), followed by Arthramid Vet with 1,346 certificates (11%). The top ten products collectively account for 58% of all certificates issued during the period. This is an informational report with no regulatory obligations or compliance requirements.
Emend 125mg Shortage, Alternative Treatments Proposed
ANSM published guidance on April 15, 2026 regarding the shortage of Emend 125mg (aprepitant) oral suspension manufactured by MSD. The drug, used in chemotherapy for children and infants aged 6 months to under 12 years, became unavailable at the end of March 2026 due to production problems. ANSM has arranged alternative supplies including Ivemend 150mg imports and authorized pharmacists to dispense magistral preparations without new prescriptions.
Mektovi (Binimetinib) 15mg and 45mg Dosage Confusion Safety Alert
ANSM issued a drug safety alert regarding Mektovi (binimetinib), an anticancer medication, following 7 reported medication errors from confusion between the 15mg and 45mg tablet dosages. The errors, which began after the 45mg dosage became available in July 2025, resulted in overdoses causing hepatocyte cytolysis, intense fatigue, nausea, serous retinal detachment, and elevated lipase levels. The recommended dose is 90mg/day (either 3 tablets of 15mg or 1 tablet of 45mg twice daily).
Aerys Medical Bed Half-Rails Safety Recall by Winncare France
ANSM has published a safety alert regarding a field safety corrective action (FSCA No. R2610462) conducted by Winncare France for Aerys and Aerys Confort sliding medical bed half-rails. Users of the affected products have received direct correspondence from Winncare France. The alert is directed to pharmacies, community care facilities, retail establishments, and home health service providers.
Scientific Reference Costenbader 2007, FDA-2026-P-3869
FDA has published a scientific reference document (Costenbader 2007) as part of docket FDA-2026-P-3869. The document was submitted as supporting scientific literature for a Pre-Market Notification submission. The actual content is restricted due to copyright and cannot be displayed.
Yang 2022 Scientific Literature Reference
A scientific literature reference authored by Yang (2022) was submitted to FDA docket FDA-2026-P-3869 as supporting documentation. The document was filed on April 3, 2025, and is accessible via regulations.gov. This appears to be part of a food additive petition or similar regulatory submission process requiring scientific literature support.
Scientific Literature Reference Rao 2017 FDA-2026-P-3869
A scientific literature reference (Rao 2017) has been submitted to FDA docket FDA-2026-P-3869. The document appears to be supporting scientific literature provided as part of comments or a submission to the FDA regulatory process. No regulatory requirements, deadlines, or penalties are established by this document submission.
Narula 2022 IBD Scientific Literature, FDA-2026-P-3869
Narula 2022 IBD Scientific Literature, FDA-2026-P-3869
Manhart 2013 Scientific Literature Submission FDA-2026-P-3869
FDA has received a docket submission to FDA-2026-P-3869 containing a citation to Manhart 2013 scientific literature. The full content of the submission is restricted due to copyright and is not publicly viewable in the docket.
Scientific Literature Reference Copyright Restricted
FDA published a document on regulations.gov (FDA-2026-P-3869-0004) regarding scientific literature references. The submission contains copyright-restricted content and is not fully accessible to the public. The document appears to be a regulatory submission or comment filed with FDA.
Citizen Petition to FDA by Kaylin Bower
A citizen petition was filed with the FDA's Center for Drug Evaluation and Research (CDER) by Kaylin Bower on April 15, 2026. The petition docket is FDA-2026-P-4104-0001. The full contents of the petition are redacted due to personally identifiable information protections, limiting visibility into the specific regulatory relief requested.
FDA Complaint FDA-2026-H-3943-0001
FDA received a complaint under docket FDA-2026-H-3943-0001 on April 15, 2025. The Center for Tobacco Products authored the complaint. The public comment period for this docket is now closed. No documents are available for viewing or download from the regulatory docket.
Scientific Literature Reference - Content Restricted
FDA received a submission on regulations.gov containing a scientific literature reference that is restricted due to copyright limitations. The specific content of the referenced literature is not accessible. The submission appears in FDA's docket system but the substantive regulatory material cannot be reviewed.
Sanchez-Guerrero 1997 Scientific Literature Reference
FDA has received and filed a scientific literature reference (Sanchez-Guerrero 1997) in regulatory docket FDA-2026-P-3869. The document has been uploaded to the public docket and is accessible to interested parties. The content of the reference cannot be displayed due to copyright restrictions.
Roche Oligonucleotides for Paternal UBE3A Expression
The European Patent Office published patent application EP3798307A1 for F. Hoffmann-La Roche AG covering oligonucleotides designed to induce paternal UBE3A expression. The invention relates to nucleic acid therapeutics targeting UBE3A gene expression, with applications in treating genetic disorders. The patent application was filed under IPC classification C12N 15/113 and designates all 39 contracting states across the European Patent Convention.
Percussionaire Corp Issues Phasitron 5 In-Line Valve Correction, Updates Use Instructions
Percussionaire Corporation issued an Urgent Medical Device Correction for the Phasitron 5 In-Line Valve (P5-TEE) due to a design limitation where leaks can occur through the pressure relief valve even when fully closed. The FDA classified this as a Class I recall, the most serious type. Leakage poses a high risk of cardiopulmonary and neurological compromise in neonatal and infant patients due to unrecognized hypoventilation, potentially causing respiratory acidosis, hypoxemia, or respiratory failure. Four serious injuries have been reported as of September 3, 2025, with no deaths.
Konkle 2012 Background Material - FDA-2026-P-3869
FDA has received and posted background material (Konkle 2012) as part of docket FDA-2026-P-3869. The document content is restricted due to copyright and is not publicly accessible. The filing represents supporting documentation submitted to the FDA docket for regulatory review.
Klaus 1982 FDA Document
FDA received a document submission dated April 15, 1982, from Klaus. The document content is restricted due to copyright and is not publicly accessible through regulations.gov. The submission is catalogued under docket FDA-2026-P-3869-0005. Specific regulatory content cannot be determined from the available metadata.
Peragallo 2018 Supporting Material FDA-2026-P-3869
FDA received supporting materials for Citizen Petition FDA-2026-P-3869 submitted by Peragallo. The document consists of 2018 supporting material referenced in the petition but the content is restricted due to copyright. The petition and supporting documentation were filed in the public docket for regulatory review.
Raglan 2019 Supporting Material
FDA received supporting material dated April 15, 2019, associated with submission FDA-2026-P-3869. The document content is restricted due to copyright. No specific regulatory requirements, deadlines, or penalties are stated in the visible portion of the document.
Ghajarzadeh 2022 Background Material for FDA Petition
FDA received background material from Ghajarzadeh dated 2022 as part of petition FDA-2026-P-3869. The submission consists of supporting documentation for a petition requesting FDA to take a specific regulatory action. The document was filed in the FDA regulations.gov docket system. No specific petition request, compliance obligations, or deadlines are stated in the available metadata.
Persson 1993 Background Material, FDA-2026-P-3869
FDA has posted background material submitted by Persson in docket FDA-2026-P-3869. The document, dated 1993, has been added to the public docket. The content is restricted due to copyright. No specific regulatory requirements or deadlines are stated in the available metadata.
Larsen 2008 FDA Document
This document (FDA-2026-P-3869-0117) appears in the FDA section of Regulations.gov. The full content is not accessible as it has been restricted due to copyright protections. No substantive regulatory requirements, deadlines, or obligations can be determined from the available metadata.
Persson 1993 Background Material Submission FDA Docket
FDA has received and placed in docket FDA-2026-P-3869 background material titled 'Persson 1993' for public access. The document contains copyrighted content that is restricted from public viewing. This appears to be historical scientific literature submitted as supporting material in an FDA regulatory proceeding. No new regulatory requirements, deadlines, or compliance obligations are established by this docket filing.
Hellwig 2016 Background Material - FDA Docket FDA-2026-P-3869
FDA received background material originally prepared in 2016 and filed in docket FDA-2026-P-3869. The document appears to be supporting documentation associated with an FDA petition. No new regulatory requirements or compliance obligations are established by this filing.
Piovani 2019 Supplemental Tables Supporting FDA Petition
FDA received supplemental tables (Piovani 2019) as supporting material filed under docket FDA-2026-P-3869. The document contains scientific data tables submitted to support a petition or submission before the agency. Affected parties should monitor this docket for related FDA actions or correspondence.
Chen 2017 Background Material, FDA-2026-P-3869, Apr 3
Chen 2017 Background Material, FDA-2026-P-3869, Apr 3
Call for Nominations for Center for Indigenous Innovation and Health Tribal Advisory Committee
The HHS Office on Minority Health (OMH) is accepting nominations for primary and alternate delegates to serve on the Center for Indigenous Innovation and Health Tribal Advisory Committee (CIIH TAC). The CIIH TAC provides tribal leaders a forum to exchange views and provide feedback on activities addressing four priority areas: research, education, service, and policy development. Nomination letters must be submitted by May 18, 2026.
CDC Agency Forms Undergo Paperwork Reduction Act Review
CDC published a notice announcing that certain agency forms are undergoing the Paperwork Reduction Act review process. The notice identifies forms under review by docket number 30Day-26-1335 and invites public comment on these information collections. Affected parties who submit information to CDC using these forms may wish to monitor the review for any changes to reporting requirements.
CDC Proposes Data Collection Under Paperwork Reduction Act
The CDC has published a notice proposing a new data collection under the Paperwork Reduction Act. The notice requests public comments on the proposed collection of information. The comment period closes 61 days from the date of publication.
CDC Proposes Data Collection Under Paperwork Reduction Act
CDC proposes a new data collection under the Paperwork Reduction Act and seeks public comments. The notice requests feedback on the proposed data collection, associated burden estimates, and collection methods. Comments are due June 15, 2026.
Advisory Council on Alzheimer's Research, Care, and Services Meeting
HHS announces a public meeting of the Advisory Council on Alzheimer's Research, Care, and Services scheduled for Monday, April 27, 2026, from 1:00 p.m. to 5:00 p.m. The meeting is open to the public for attendance and comment participation. This is a routine advisory council meeting announcement with no new compliance obligations.
CMS Schedules June 2026 Public Meeting on HCPCS Level II Code Revisions
CMS announces the first biannual 2026 public meeting for HCPCS Level II coding to discuss preliminary coding, Medicare benefit category, and payment determinations for new non-drug and non-biological items and services. The primary meeting is scheduled for June 1, 2026, in Baltimore with a virtual overflow option on June 2, 2026. Speaker registration and in-person attendance requests are due by May 18, 2026, and written comments may be submitted until June 3, 2026.
RSV Vaccine Factsheet – Information for Patients, Parents and Carers
The MHRA published a new patient factsheet on RSV vaccination on 15 April 2026. The factsheet provides comprehensive information about respiratory syncytial virus (RSV), including eligibility criteria, safety and effectiveness of vaccines used in the UK, side effects, pregnancy considerations, and contraindications. The document is designed to help patients, parents, and carers understand RSV vaccines and make informed decisions about vaccination.
Cancer Vaccine Patent hESCs TLR3 Adjuvant Assigned to INSERM
USPTO granted patent US12599662B2 to INSERM for a cancer vaccine composition using irradiated human embryonic stem cells combined with a TLR3 adjuvant. The patent covers methods for treating cancers including breast cancer by inducing MHC-I presentation of antigens. The patent includes 16 claims.
USPTO Patent US12601742B2 for Endometrial Cancer Treatment Methods
USPTO granted patent US12601742B2 to Mayo Foundation for Medical Education and Research covering methods and materials for assessing and treating endometrial cancer. The patent covers methods for identifying endometrial cancers likely to respond to particular cancer treatments by assessing combinations of mutations and expression levels, such as platinum-based therapies. The patent contains 22 claims.
Sudan Crisis, 4M Malnourished, 37% Health Facilities Closed
WHO reports that three years of conflict in Sudan have created the world's largest humanitarian and displacement crisis. Nearly 4 million people are estimated to be acutely malnourished in 2026, with disease outbreaks including malaria, dengue, measles, and polio spreading across multiple states. Some 37% of health facilities across Sudan's 18 states remain non-functional, while WHO has verified 217 attacks on health care since April 2023.
Safety Assessment of Genome Editing Human Gene Therapy Products Using Next-Generation Sequencing
FDA's Center for Biologics Evaluation and Research has issued draft guidance recommending next-generation sequencing (NGS)-based methods for assessing safety of human genome editing gene therapy products in nonclinical studies. The guidance addresses evaluation of off-target editing risks and genome integrity for products supporting IND and BLA applications. Comments are being accepted via regulations.gov under docket FDA-2026-D-1255.
Center for Scientific Review Notice of Closed Meetings
The National Institutes of Health Center for Scientific Review announces five closed meetings scheduled for May 12-13, 2026. The meetings will review and evaluate grant applications for clinical vision research, reproductive/perinatal/pediatric health, contraceptive development, immunity/host defense, and aging tissue research. Meetings are closed under provisions of the Federal Advisory Committee Act because discussions could disclose confidential trade secrets, commercial property such as patentable material, and personal information of individuals associated with grant applications.
Center for Scientific Review Notice of Closed Meetings
The NIH Center for Scientific Review announces five closed meetings scheduled for May 8, 2026. Review panels will evaluate grant applications in oncological sciences, medical informatics, genetics, endocrinology, and career development awards. Meetings are closed pursuant to the Federal Advisory Committee Act due to confidential grant information.
Increasing Access to Nonprescription Drugs; Public Meeting; Request for Comments
The FDA announced a public meeting on April 23, 2026 to gather stakeholder perspectives on increasing access to nonprescription drugs. The meeting will be held virtually and in person at the National Press Club in Washington, DC. Written and electronic comments are due by May 8, 2026.
Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry
FDA announced availability of draft guidance providing recommendations for next-generation sequencing (NGS)-based methods used in nonclinical studies to support initiation of clinical trials of investigational human genome editing products. The draft guidance is open for public comment until July 14, 2026 (90-day comment period). Comments should be submitted to Docket No. FDA-2026-D-1255.
Financial Transparency and Efficiency of PDUFA, BsUFA, and GDUFA; Public Meeting
The FDA is announcing a public meeting on June 23, 2026, to discuss financial transparency and efficiency of the Prescription Drug User Fee Act (PDUFA), Biosimilar User Fee Act (BsUFA), and Generic Drug User Fee Amendments (GDUFA). The hybrid meeting will be held at FDA White Oak Campus and via Microsoft Teams. Written and electronic comments on the meeting topic must be submitted by July 23, 2026.
Peptide Amide Composition for Kappa Opioid Receptor Treatment
USPTO granted Patent US12599647B2 to Xizang Haisco Pharmaceutical Co., Ltd. for a peptide amide composition containing a compound of formula (I) and pH regulators (pH 3-5.5). The composition is designed for treating or preventing diseases or conditions associated with kappa opioid receptors. The patent includes 19 claims and covers the compound composition, preparation methods, and medical applications.
Nestlé Granted Patent for Green Coffee Insulin Treatment Composition
USPTO granted Patent US12599643B2 to Societe des Produits Nestle S.A. for green coffee-based compositions comprising hydrolysed chlorogenic acid for improving insulin profile. The patent covers compositions for treating or preventing disorders linked to increased plasma postprandial insulin, including esterase treated decaffeinated green coffee extract with 40-200 mg daily dosage. The patent contains 16 claims and was filed March 27, 2020.
Thrombolytic Agents for Intravascular Clots - US12599653B2
The USPTO granted Patent US12599653B2 to Jinis Co., Ltd. for a thrombolytic agent comprising a dual-domain polypeptide with a thrombo-recognition domain and a thrombolytic domain effective for dissolving intravascular thrombus. The patent covers a pharmaceutical composition designed to prevent and treat thrombosis with reduced bleeding side effects compared to conventional thrombolytic therapies. The patent application was filed October 19, 2020, under Application No. 17770795.
CyPep-1 Peptide Composition for Treating Neoplastic Lesions
USPTO granted patent US12599646B2 to CYTOVATION ASA covering a pharmaceutical composition comprising therapeutic peptide CyPep-1 for treating neoplastic lesions, particularly warts. The patent, with 16 claims, was filed on March 10, 2020, and includes CPC classifications related to peptide formulations and therapeutic applications.
Acellular Amniotic Fluid for Ischemic Injury Treatment
USPTO granted patent US12599635B2 to University of Utah Research Foundation covering compositions and methods for treating ischemic injuries using acellular amniotic fluid (acAF). The patent names inventors Hadi Javan, Craig H. Selzman, Young Sook Lee, Jo-Anna Reems, and Jan L. Pierce, and includes 31 claims. The patent application was filed March 22, 2021 under application number 17912730.
Cytotoxic Imidazopyridine Compounds and Their Use in Therapy
The USPTO granted Patent US12599676B2 to MyricX Pharma Limited for cytotoxic imidazo[1,2-A]pyridine compounds and their therapeutic use. The patent covers compounds of formula (I) classified under A61P 35/00 for cancer therapy. The application (19072750) was filed March 6, 2025, and the patent contains 23 claims.
Integrin α10-Selected MSCs Treat Skin Defects
USPTO granted patent US12599633B2 to Xintela AB covering integrin α10-selected mesenchymal stem cell compositions for treating skin defects, with 20 claims. The patent protects cell populations and culture conditions that enhance viability and regenerative function in wound healing applications.
Demethylating Agent Melanoma Treatment Method Using STING Signaling Enhancement
USPTO granted patent US12599621B2 to H. Lee Moffitt Cancer Center covering methods for enhancing anti-tumor T cell responses in melanoma subjects with defective STING signaling using demethylating agents. The patent, filed January 21, 2021, includes claims to methods of treatment involving demethylating agents, STING agonists, and tumor infiltrating lymphocytes. Inventors: James Mulé, Rana Falahat, Glen Barber.
US12599620B2 - Chronic Fatigue Syndrome Plasma Cell Inhibitor Treatment Method
The USPTO granted Patent US12599620B2 to Vestlandets Innovasjonsselskap AS covering a method for treating chronic fatigue syndrome using inhibitory or cytotoxic agents against plasma cells. The patent also claims combinations of plasma cell-targeting agents with B-cell depleting agents or B-cell activation inhibitors. The patent application was filed on August 31, 2020, under application number 17638453, and contains 3 claims.
MaxCyte Electroporation Device Design Patent USD1122471S1
The USPTO granted Design Patent USD1122471S1 to MaxCyte, Inc. for an electroporation device design. The patent application was filed on March 5, 2025, with inventors James William Luther, Bertold Engler, Andrea Besana, and Thomas Alan Peach. One design claim was granted. Design patents protect the ornamental appearance of a functional item for a term of 15 years from grant date.
Pharmaceuticals and Dosing Means for Human Aging Reversal
The USPTO granted patent US12599651B2 to Intervene Immune Inc. on April 14, 2026. The patent covers pharmaceutical compositions combining human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin for reversing age-related changes including systemic inflammation, cancer risk, thymus function, immune cell populations, and epigenetic age. The patent contains 11 claims.
SIRPγ Inhibitor for Cancer Treatment | US12599650B2
USPTO granted patent US12599650B2 to AMGEN INC. covering methods of treating tumors or cancer using SIRPγ inhibitors. The patent, invented by Ruozhen Hu, Paolo Manzanillo, and Wenjun Ouyang, contains 9 claims. Filing date was June 23, 2020 (Application No. 17618922).
Kyprolis Visible Particles After Reconstitution - Safety Communication
Swissmedic issued a health professional communication regarding Kyprolis (carfilzomibum) 10 mg and 60 mg following routine stability monitoring that detected visible particles (transparent, colorless) in reconstituted samples. All distributed batches remain safe for use. The communication emphasizes strict adherence to visual inspection procedures per approved reconstitution instructions before administration.
Draeger Atlan A350 and A350 XL Anesthesia Workstation Correction
FDA classified Draeger Atlan A350 and A350 XL anesthesia workstations as a Class I recall—the most serious type—due to potential piston ventilator failure before or during use. Draeger is instructing customers to inspect and, if necessary, replace the ventilator motor assembly. Healthcare providers may continue using affected devices under permanent supervision until the corrective action is implemented.
US12599617B2 Methods of Treating Head and Neck Cancers with Hemp Extract Containing CBD
The USPTO granted Patent US12599617B2 to Dove Innovation Pty Limited covering methods of treating head and neck cancers using compositions containing hemp-derived CBD. The patent, with 17 claims, specifically covers mucosal formulations of cannabis extract for cancer treatment. Inventors include Alexandra M. Capano, Pradeep Singh Tanwar, and Alex Nance.
Method of Obtaining Pharmaceutical Agent Inhibiting HeLa Cervical Cancer Cells
USPTO granted Patent US12599626B2 to LLC 'Laboratory of Innovative Technologies' on April 14, 2026. The patent covers a method for producing a pharmaceutical agent for inhibiting proliferation of HeLa cervical cancer cells using metal powder obtained via electric wire explosion of low-carbon steel. The invention involves exploding wire with specific energy of 7-18 KJ/g in carbon monoxide, followed by passivation, mixing with RPMI-1640 nutrient medium, and phase separation to produce the therapeutic agent.
US12599625B2 - Nitrous Oxide Oxygen Inhalation Therapy for ARDS
The USPTO granted Patent US12599625B2 to Penland Foundation on April 14, 2026, covering nitrous oxide and oxygen inhalation therapy for treating ARDS and conditions caused by elevated cytokine levels. The patent, invented by Roland M. Williams, contains 22 claims classified under A61K 33/00 and A61P 11/16. The treatment method involves administering nitrous oxide and oxygen by inhalation before, during, and/or after ARDS occurs to address acute cytokine system activation from infections, injuries, or other conditions.
Therapy Efficacy Method via Tissue Analysis, Arion Diagnostics
USPTO granted Patent US12599349B2 to Arion Diagnostics, Inc. covering a method for determining therapeutic agent efficacy through non-invasive biological tissue characterization. The method involves measuring molecular structure of tissue at two time points and observing changes to determine efficacy. The patent includes 27 claims and covers therapeutic applications across multiple CPC classifications including oncology, immunology, and neurological disorders.
Tricyclic KRAS Inhibitor Patent - Incyte Corporation
The USPTO granted Patent US12600717B2 to Incyte Corporation on April 14, 2026 for tricyclic compounds as inhibitors of KRAS activity. The patent contains 34 claims covering Formula I compounds useful in treating diseases associated with KRAS activity, including cancer. Filing date was July 13, 2022, under application number 17812310.
Salt Inducible Kinase Inhibitors Patent Granted to General Hospital Corporation
USPTO granted patent US12600719B2 to General Hospital Corporation covering salt inducible kinase (SIK) inhibitor compounds and pharmaceutical compositions. Inventors Marc Nathan Wein and William J. Greenlee filed the application on August 5, 2021. The patent contains 20 claims under CPC classification C07D 471/04.
Tetracyclic DGK Inhibitor Compounds for Cancer Treatment
USPTO granted Patent US12600722B2 to Incyte Corporation for tetracyclic compounds that modulate diacylglycerol kinase (DGK) activity, useful in treating cancer including solid tumors. The patent names Joshua Hummel, Shicheng Shi, and Xiaozhao Wang as inventors and contains 63 claims.
Nanjing University of Chinese Medicine - US12600724B2 Indole Alkaloid Compound and Preparation Method
The USPTO granted Patent US12600724B2 to Nanjing University of Chinese Medicine for an indole alkaloid compound represented by formula (I), including its preparation method and pharmaceutical salts. The compound has demonstrated therapeutic effects in animal studies, including promoting axon growth in peripheral sensory neurons, improving nerve conduction velocity in diabetic rats, accelerating foot ulcer wound healing, reducing pulmonary fibrosis, and protecting lung tissues. The patent contains 13 claims covering the compound, formulations, and methods of treatment for diabetic complications.
Vanderbilt Cyclopropylpiperidine M4 Antagonists - US12600726B2
The USPTO granted Patent No. US12600726B2 to Vanderbilt University on April 14, 2026, covering cyclopropylpiperidine compounds useful as antagonists of muscarinic acetylcholine receptor M4 (mAChR M4). The patent includes 15 claims and covers methods of making the compounds, pharmaceutical compositions, and methods of treating disorders using the compounds. Vanderbilt University receives enforceable IP rights for this therapeutic compound class.
Washington University Patent for Toxoplasma Gondii Treatment Compounds
The USPTO granted Patent US12600727B2 to Washington University on April 14, 2026, covering compounds and methods for treating infections caused by Toxoplasma gondii and related parasites. The patent includes 18 claims and lists inventors L. David Sibley, Joshua Radke, Eamon Comer, Marshall Morningstar, and Bruno Melillo. This grant provides Washington University with exclusive intellectual property rights for the developed antiparasitic compounds and their pharmaceutical applications.
Interleukin-17 Inhibitors Patent - Novartis AG
The USPTO granted patent US12600728B2 to NOVARTIS AG covering novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds as Interleukin-17 (IL-17) inhibitors. The patent also protects processes for preparing these compounds, pharmaceutical compositions, and medicaments for treating diseases and disorders mediated by IL-17.
ONO Pharmaceutical ABHD6 Antagonist Patent US12600730B2
USPTO granted Patent US12600730B2 to ONO Pharmaceutical Co., Ltd. on April 14, 2026, covering substituted cyclopenta[c]pyrrole compounds as ABHD6 antagonists for pharmaceutical use. The patent includes 18 claims for compounds useful in preventing or treating diseases associated with ABHD6 enzyme inhibition. The application was filed on April 8, 2024.
NURIX BTK Degrading Compounds, 36 Claims, Apr 14
The USPTO granted Patent US12600732B2 to NURIX THERAPEUTICS, INC. on April 14, 2026. The patent covers 36 claims for bifunctional compounds that degrade BTK via the ubiquitin proteolytic pathway, along with pharmaceutical compositions and methods of treatment for various diseases, conditions, or disorders.
ELI LILLY AND COMPANY - KRAS Inhibitor Compounds for Cancer Treatment Patent Grant
The USPTO granted Patent US12600733B2 to Eli Lilly and Company on April 14, 2026, covering KRAS inhibitor compounds for treating cancer. The patent includes 30 claims for compounds of specified formula and their use in pharmaceutical compositions. Filing date was September 30, 2025.
Interoperability Standards for Prior Authorization APIs for Medicare Advantage, Medicaid, CHIP, and QHP Issuers
CMS proposes requiring Medicare Advantage organizations, Medicaid FFS programs, CHIP FFS programs, Medicaid managed care plans, CHIP managed care entities, and QHP issuers on FFEs to implement electronic prior authorization APIs for drugs. The rule would extend existing interoperability requirements to cover drug prior authorizations, adopt HL7 FHIR standards as HIPAA-covered transaction standards, require API endpoint reporting to CMS, and add a definition of failure to report for civil monetary penalty purposes.
FDA Center for Tobacco Products Files Complaint - April 2026
The FDA Center for Tobacco Products (CTP) filed a complaint on April 14, 2026, initiating a formal enforcement action against tobacco product manufacturers. The complaint was submitted to regulations.gov under docket FDA-2026-H-3832. This filing represents FDA's regulatory enforcement mechanism for addressing violations of tobacco product standards under the Family Smoking Prevention and Tobacco Control Act.
FDA Center for Tobacco Products Complaint Submission
The FDA Center for Tobacco Products received a complaint document under docket FDA-2026-H-3868. The comment period has closed and no documents are available for public viewing. The nature and content of the complaint are not accessible through the regulatory filing system.
Acknowledgment Letter to Mom3nts Production
FDA's Center for Devices and Radiological Health (CDRH), Division of Manufacturers and Communication (DMB), issued an acknowledgment letter to Mom3nts Production. The letter confirms receipt of a submission filed under docket FDA-2025-V-3791. No documents are available for public viewing on Regulations.gov; the letter content is contained in an attachment.
Halozyme US12600959B2 - Modified PH20 Hyaluronidase Polypeptides
USPTO granted Patent US12600959B2 to Halozyme, Inc. covering modified PH20 hyaluronidase polypeptides with enhanced stability and activity. The patent includes 15 claims spanning formulations, compositions, and uses thereof. Filing date was March 5, 2025, with application number 19071345.
Isoxazolo[5,4-H]quinazoline CDK Inhibitor Patent
USPTO granted patent US12600731B2 to Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. for isoxazolo[5,4-H]quinazoline compounds effective as cyclin-dependent kinase (CDK) inhibitors for treating cell proliferation disorders. The patent contains 23 claims and covers pharmaceutical compositions and methods of treating CDK-mediated diseases.
Benzazepine derivative for vasopressin receptor disease treatment
Benzazepine derivative for vasopressin receptor disease treatment
Dexcom G7 iOS CGM App Type II Recall - Display Flicker Issue
Health Canada issued a Type II medical device recall for Dexcom G7 iOS CGM App versions 2.9.0 to 2.11.2 (model SW12300). The affected apps display a flicker that sequentially shows previous Estimated Glucose Values before displaying the current reading. Users are advised to contact Dexcom, Inc. for additional information. The recall was published April 14, 2026, with recall date April 9, 2026.
Nitrous Oxide Chargers: Sold for Inhalation Without Market Authorization
Health Canada has issued a Type I recall for PUR GAS Cream Charger nitrous oxide products sold without Drug Identification Number (DIN) market authorization. The products, sold in multiple flavours including Blue Raspberry, Mango, and Grape, were marketed for inhalation purposes. Posh Glass Inc. of Calgary, Alberta is the affected company. Retailers are required to remove these products from the Canadian market.
Revolution Ascend CT Security Vulnerability Recall
Health Canada issued a Type II medical device recall for GE Healthcare Japan Corporation's Revolution Ascend CT systems due to a potential security vulnerability in the AW server deployed via Edison Health Link (EHL) based CT smart subscription. Three lots are affected: AS10G2400087YC, AS10G2400056YC, and AS10G2400081YC, all with model/catalogue number 00840682146173. Healthcare providers using these devices should contact the manufacturer for additional information regarding the cybersecurity vulnerability.